DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP POWDER FOR SOLUTION

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Kup teraz

Składnik aktywny:

DOXORUBICIN HYDROCHLORIDE

Dostępny od:

PANDA PHARMACEUTICALS INC.

Kod ATC:

L01DB01

INN (International Nazwa):

DOXORUBICIN

Dawkowanie:

50MG

Forma farmaceutyczna:

POWDER FOR SOLUTION

Skład:

DOXORUBICIN HYDROCHLORIDE 50MG

Droga podania:

INTRAVENOUS

Sztuk w opakowaniu:

100

Typ recepty:

Prescription

Dziedzina terapeutyczna:

ANTINEOPLASTIC AGENTS

Podsumowanie produktu:

Active ingredient group (AIG) number: 0110825003; AHFS:

Status autoryzacji:

APPROVED

Data autoryzacji:

2017-08-16

Charakterystyka produktu

                                _Doxorubicin Hydrochloride for Injection USP _
_ _
_ _
_ _
_Page 1_
_ of 43_
_ _
PRODUCT MONOGRAPH
PR DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP 50 MG / VIAL
Sterile Powder for Solution - Intravenous
THERAPEUTIC CLASSIFICATION
Antineoplastic Agent
PANDA PHARMACEUTICALS INC.
35 Nixon Road Unit 10
Caledon, ON
L7E 1K1
Control # 195868
Date of Preparation: August 11, 2017
_Doxorubicin Hydrochloride for Injection USP _
_ _
_ _
_ _
_Page 2_
_ of 43_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...............................................................................................
10
DRUG INTERACTIONS
................................................................................................
11
DOSAGE AND ADMINISTRATION
..............................................................................
12
OVERDOSAGE
............................................................................................................
16
STORAGE AND STABILITY
.........................................................................................
16
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 18
PART II: SCIENTIFIC INFORMATION
...........................................................................
18
PHARMACEUTICAL INFORMATION
...........................................................................
18
CLINICAL TRIALS
.........................
                                
                                Przeczytaj cały dokument
                                
                            

Dokumenty w innych językach

Charakterystyka produktu Charakterystyka produktu francuski 17-08-2017

Wyszukaj powiadomienia związane z tym produktem